Anti-interferon-alpha antibodies
AssigneeGenentech, Inc.
InventorsAnan Chuntharapai, Jin K. Kim, Leonard G. Presta, Timothy Stewart
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to the generation and characterization of neutralizing anti-IFN-α monoclonal antibodies with broad reactivity against various IFN-α subtypes. The invention further relates to the use of such anti-IFN-α antibodies in the diagnosis and treatment of disorders associated with increased expression of IFN-α, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE).
Claims54
An anti-IFN-α monoclonal antibody which binds to and neutralizes a biological activity of at least IFN-α subtypes, IFN-α1, IFN-α2, IFN-α4, IFN-α5, IFN-α8, IFN-α10, and IFN-α21.
An anti-IFN-α antibody light chain or a fragment thereof, comprising the following CDR's:
- (a) L1 of the formula RASQSVSTSSYSYMH (SEQ ID NO:
- 7);
- (b) L2 of the formula YASNLES (SEQ ID) NO:
- 8);
- and
- (e) L3 of the formula QHSWGIPRTF (SEQ ID NO:
- 9).
An anti-IFN-α antibody heavy chain or a fragment thereof, comprising the following CDR's:
- (a) H1 of the formula GYTFTEYIIH (SEQ ID) NO:
- 10);
- (b) H2 of the formula SINPDYDITNYNQRFKG (SEQ ID) NO:
- 11);
- and
- (c) H3 of the formula WTSDFFDY (SEQ ID) NO:
- 12).
An anti-IFN-α antibody comprising
- (A) at least one light chain or a fragment thereof, comprising the following CDR's:
- (a) L1 of the formula RASQSVSTSSYSYMH (SEQ ID NO:
- 7);
- (b) L2 of the formula YASNLES (SEQ ID NO:
- 8);
- and
- (c) L3 of the formula QHSWGIPRTF (SEQ ID NO:
- 9);
- and
- (B) at least one heavy chain or a fragment thereof, comprising the following CDR's:
- (a) H1 of the formula GYTFTEYIIH (SEQ ID NO:
- 10);
- (b) H2 of the formula SINPDYDITNYNQRFKG (SEQ ID NO:
- 11);
- and
- (c) H3 of the formula WISDFFDY (SEQ ID NO:
- 12).
An isolated nucleic acid molecule comprising the light chain polypeptide-encoding nucleic acid sequence of the vector deposited with ATCC on Jan. 9, 2001 and having accession No. PTA-2882.
An isolated nucleic acid molecule comprising the heavy chain polypeptide-encoding nucleic acid sequence of the vector deposited with ATCC on Jan. 9, 2001 and having accession No. PTA-2881.
A hybridoma cell line deposited with ATCC on Jan. 18, 2001 and having accession No. PTA-2917.
Dependencies are inferred from the claim text.